Subject
Genetics(clinical),Hematology,General Medicine
Reference14 articles.
1. 1 A. Srivastava, How are the issues defined? In: World Federation of Hemophilia Third Global Forum on the Safety and Safety of Hemophilia Treatment Products. Available at: http://www.wfh.org/Content_Documents/Other_Publications/Global_Forum_2003.pdf. Last accessed 21 April 2004 .
2. The Upward Spiral of Drug Costs: A Time Series Analysis of Drugs Used in the Treatment of Hemophilia
3. 3 A. Farrugia Variant Creuzfeldt-Jakob disease and haemophilia - a risk assessment of plasma-derived products. Available at: http://www.wfh.org/Content_Documents/Blood_Safety/vCJD_Bulletin2_revised.pdf. Last accessed 5 May 2004.
4. 4 A. Farrugia Plasma for fractionation. Safety and quality issues.Haemophilia2004, 10 : 334 -40 .
5. Controversies in transfusion medicine. Should donor hemoglobin standards be lowered? Con
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献